NS-018 Phase 1/2 trials in the United States
First written in FY2017-Q1. 20 of 25 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual report
「The Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, that had been conducted overseas was discontinued.」
The status of the NS-018 Phase 2 trial overseas changed from ongoing to discontinued. - FY2024-Q3RestatedAnnual report
「A Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently underway overseas.」
The status of the ongoing Phase 2 trial of NS-018 overseas is being reiterated. - FY2024-Q2RestatedAnnual report
「A Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently underway overseas.」
The status of the ongoing Phase 2 trial of NS-018 overseas is being reiterated. - FY2024-Q1RestatedAnnual report
「A Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently underway overseas.」
The status of the ongoing Phase 2 trial of NS-018 overseas is being reiterated. - FY2023AdvancedAnnual report
「A Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently underway overseas.」
NS-018 advanced from the previous stage of preparing a subsequent trial to the stage of conducting a Phase 2 trial overseas. - FY2023-Q2ReframedAnnual report
「A Phase 2 trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently being prepared overseas.」
The description of NS-018's development status has been revised from preparation for a subsequent trial in the United States to preparation for a Phase 2 trial overseas. - FY2022-Q3RestatedAnnual report
「A subsequent trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2022-Q2RestatedAnnual report
「A subsequent trial of NS-018 (generic name: ilginatinib), a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2022-Q1RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2021RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2021-Q3RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2021-Q2RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2021-Q1RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2020-Q3RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2020-Q2RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2020-Q1RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2019-Q3RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2019-Q2RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2019-Q1RestatedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The status of preparation for a subsequent NS-018 trial in the United States is being reiterated. - FY2018-Q3AdvancedAnnual report
「A subsequent trial of NS-018, a treatment for myelofibrosis, is currently being prepared in the United States.」
The description of NS-018 has advanced from the previous status of an ongoing Phase 1/2 trial to the preparation stage for a subsequent trial. - FY2018-Q2RestatedAnnual report
「A Phase 1/2 trial of NS-018, a treatment for myelofibrosis, is currently underway in the United States.」
The NS-018 Phase 1/2 trial remains ongoing in the United States. - FY2018-Q1RestatedAnnual report
「A Phase 1/2 trial of NS-018, a treatment for myelofibrosis, is currently underway in the United States.」
The NS-018 Phase 1/2 trial remains ongoing in the United States. - FY2017-Q3RestatedAnnual report
「A Phase 1/2 trial of NS-018, a treatment for myelofibrosis, is currently underway in the United States.」
The NS-018 Phase 1/2 trial remains ongoing in the United States. - FY2017-Q2RestatedAnnual report
「A Phase 1/2 trial of NS-018, a treatment for myelofibrosis, is currently underway in the United States.」
The status of the ongoing NS-018 Phase 1/2 trial in the United States is being reiterated. - FY2017-Q1First statedAnnual report
「A Phase 1/2 trial of NS-018, a treatment for myelofibrosis, is currently underway in the United States.」
It is stated that a Phase 1/2 trial of NS-018 is currently underway in the United States.